藥物交互作用
Nivolumab + Thalidomide
嚴重程度: 嚴重
Nivolumab and Thalidomide: major interaction.
最後更新
僅供醫療專業人員參考。本頁為簡要摘要，並非醫療建議，亦不能取代官方仿單或臨床判斷。開立處方或調劑前請務必核實。
本頁的臨床內容僅提供英文版。
摘要
Thalidomide is an immunomodulator, and concurrent use with PD-1 antibodies in multiple myeloma has been linked to excess mortality in trials of pembrolizumab combinations. Nivolumab is expected to share this class risk, though direct evidence is limited. Outside a clinical trial the combination offers no proven benefit.
用白話說明這項交互作用的意義
Nivolumab and Thalidomide can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Nivolumab belongs to Oncology; Thalidomide belongs to Miscellaneous.
為什麼會發生
Combined immune modulation with PD-1 blockade and thalidomide analogs; the mechanism of excess harm is not fully established.
處置方式
Avoid combining nivolumab with thalidomide or related agents in multiple myeloma outside a clinical trial. If used, monitor closely for immune-related adverse events and infections.
可向藥師詢問的問題
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Nivolumab 的其他交互作用
Thalidomide 的其他交互作用
常見問題
Can I take Nivolumab with Thalidomide?
MediHelp rates the interaction as major. Nivolumab and Thalidomide can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Thalidomide is an immunomodulator, and concurrent use with PD-1 antibodies in multiple myeloma has been linked to excess mortality in trials of pembrolizumab combinations. Nivolumab is expected to share this class risk, though direct evidence is limited. Outside a clinical trial the combination offers no proven benefit.
How serious is the interaction between Nivolumab and Thalidomide?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid combining nivolumab with thalidomide or related agents in multiple myeloma outside a clinical trial. If used, monitor closely for immune-related adverse events and infections.
What other medicines interact with Nivolumab?
MediHelp also lists interactions of Nivolumab with, for example, Dexamethasone-tobramycin, Dexamethasone, Efgartigimod / hyaluronidase sc. The full list is on the Nivolumab page.
在 MediHelp App 中取得完整藥品專論、劑量資訊與交互作用檢查
在 MediHelp App 中開啟完整參考資料、檢查多種藥物間的交互作用，並使用劑量工具。
